Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (40 ops.)
Latest filing published 04 Sept 2026 for Kymera Therapeutics, Inc., €120k. Read the official filing
Filing timeline
BuySaleBrian Adams
Insider track record
Disclosed buys
0
Disclosed sells
40
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Brian Adams: trading record in brief
Brian Adams (board member) discloses dealings in 3 companies, chiefly Relay Therapeutics, Inc., Keryx Biopharmaceuticals Inc and Kymera Therapeutics, Inc. In total, 50 filings cover trades dated from 5 January 2016 to 4 September 2026.
On the market, this insider has only sold: 40 sales, €1.3M in total. The amount is not disclosed for 4 filings. Other entries cover 7 share grants and 3 option exercises. In 2026 alone, the filings show no purchases and 3 sales.
Most recently, on 4 September 2026, the filings show an open-market sale worth €120k in Kymera Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Brian Adams
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations50 total
1,209 shares@ US$115.550.0014% mcap18.8% of flowCommon StockSEC:0001193125-26-383874:0
3,025 shares@ US$116.810.0036% mcap47.5% of flowCommon StockSEC:0001193125-26-383874:1
2,137 shares@ US$117.570.0026% mcap33.8% of flowCommon StockSEC:0001193125-26-383874:2
4,125 shares0Common StockSEC:0001193125-26-091986:0
52,500 shares0Common StockSEC:0001193125-25-195044:0
1,637 shares@ US$3.740.9% of flowCommon StockSEC:0000950170-25-100364:0
1,644 shares@ US$3.170.7% of flowCommon StockSEC:0000950170-25-061364:0
12,943 shares@ US$3.005.1% of flowCommon StockSEC:0000950170-25-061364:1
298 shares@ US$2.840.1% of flowCommon StockSEC:0000950170-25-047717:0
33,688 shares@ US$4.6322.3% of flowCommon StockSEC:0000950170-25-011311:0
299 shares@ US$4.380.2% of flowCommon StockSEC:0000950170-24-141599:0
1,632 shares@ US$6.061.4% of flowCommon StockSEC:0000950170-24-118974:0
295 shares@ US$7.510.3% of flowCommon StockSEC:0000950170-24-110804:0
1,638 shares@ US$8.852.0% of flowCommon StockSEC:0000950170-24-088811:0
295 shares@ US$6.260.3% of flowCommon StockSEC:0000950170-24-079684:0
1,623 shares@ US$6.381.4% of flowCommon StockSEC:0000950170-24-050151:0
348 shares@ US$7.700.4% of flowCommon StockSEC:0000950170-24-038655:0
1,929 shares@ US$9.642.6% of flowCommon StockSEC:0001209191-24-002468:0
200,000 shares0Common StockSEC:0001209191-24-001835:0
294 shares@ US$11.510.5% of flowCommon StockSEC:0001209191-23-059991:0
1,632 shares@ US$6.031.4% of flowCommon StockSEC:0001209191-23-054016:0
294 shares@ US$8.380.6% of flowCommon StockSEC:0001209191-23-050857:0
1,628 shares@ US$11.802.6% of flowCommon StockSEC:0001209191-23-043834:0
294 shares@ US$12.120.5% of flowCommon StockSEC:0001209191-23-040054:0
1,936 shares@ US$11.162.9% of flowCommon StockSEC:0001209191-23-033410:0
25 of 50 declarations
